Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies

(2018) Eduardo Vadillo et al.   BLOOD REVIEWS

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Drug discovery targeting the mTOR pathway

(2018) Alberto M. Martelli et al.   CLINICAL SCIENCE

Everolimus is a new anti-cancer molecule: Metabolic side effects as lipid disorders and hyperglycemia

(2018) L. Morviducci et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The rocky road to personalized medicine in acute myeloid leukaemia

(2018) Bryan Brinda et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine

(2018) Xiaomo Wu et al.   Journal of Proteomics

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells

(2018) Pedro Casado et al.   LEUKEMIA

Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia

(2018) Sarah D. Cramer et al.   LEUKEMIA

PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy

(2018) Nahal Haddadi et al.   Molecular Cancer

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Personalization of prostate cancer therapy through phosphoproteomics

(2018) Wei Yang et al.   Nature Reviews Urology

Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia

(2018) Andrew E. Place et al.   PEDIATRIC BLOOD & CANCER

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy

(2018) Olga Ksionda et al.   PLoS One

Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by DEPTOR

(2018) Thawfeek M. Varusai et al.   Scientific Reports

Chemotactic Cues for NOTCH1-Dependent Leukemia

(2018) Erich Piovan et al.   Frontiers in Immunology

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression

(2018) Ellie Rad et al.   Cancers

Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies

(2018) Martina Gatzka   Cancers

mTOR Pathways in Cancer and Autophagy

(2018) Mathieu Paquette et al.   Cancers

New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update

(2018) Adrián Montaño et al.   Cancers

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

(2017) Zongbi Yi et al.   Journal of Breast Cancer

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

(2017) Jop C. Teepen et al.   JOURNAL OF CLINICAL ONCOLOGY

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

Therapeutic targeting of CK2 in acute and chronic leukemias

(2017) F Buontempo et al.   LEUKEMIA

Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD

(2017) T Yuan et al.   LEUKEMIA

PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature

(2017) Evgeni Efimenko et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

(2017) Haijuan Yang et al.   NATURE

Clonal evolution in leukemia

(2017) Adolfo A Ferrando et al.   NATURE MEDICINE

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

(2017) Mark Davies et al.   Orphanet Journal of Rare Diseases

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

(2017) Seraina Faes et al.   Oxidative Medicine and Cellular Longevity

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

(2017) David M. Sabatini   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia

(2017) P Richter-Pechańska et al.   Blood Cancer Journal

The Mammalian Target of Rapamycin and DNA methyltransferase 1 axis mediates vascular endothelial dysfunction in response to disturbed flow

(2017) Yun-Peng Zhang et al.   Scientific Reports

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

(2016) N. Jain et al.   BLOOD

4EBP1/c-MYC/PUMA and NF- B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

(2016) S. Yun et al.   BLOOD

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells

(2016) Seohyun Park et al.   BMB Reports

Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

(2016) L. Moscetti et al.   BREAST

The therapeutic potential of mTOR inhibitors in breast cancer

(2016) Linda S. Steelman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Targeting mTOR for the treatment of B cell malignancies

(2016) Jong-Hoon Scott Lee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

(2016) Yana Pikman et al.   CLINICAL CANCER RESEARCH

Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies

(2016) Lingbao Gao et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications

(2016) V. Gianfelici et al.   HAEMATOLOGICA

Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity

(2016) Alice Melão et al.   HAEMATOLOGICA

The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia

(2016) R. D. Mendes et al.   HAEMATOLOGICA

Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia

(2016) Peter J. Siska et al.   JOURNAL OF IMMUNOLOGY

Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling

(2016) Laixi Bi et al.   Journal of Translational Medicine

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

(2016) K Canté-Barrett et al.   LEUKEMIA

Adult Acute Lymphoblastic Leukemia

(2016) Shilpa Paul et al.   MAYO CLINIC PROCEEDINGS

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors

(2016) Seraina Faes et al.   Molecular Cancer

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia

(2016) Y Hu et al.   ONCOGENE

Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation

(2016) Todd A. Triplett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New structural and functional insight into the regulation of Ras

(2016) Yoshihito Kano et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation

(2016) Weiyuan Wang et al.   Oncotarget

Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death

(2016) Valeria Tosello et al.   Oncotarget

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

(2016) Bo Mi Ku et al.   Oncotarget

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia

(2016) Etienne Danis et al.   Cell Reports

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

(2016) Yunlei Li et al.   PLOS MEDICINE

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications

(2016) V. Gianfelici et al.   HAEMATOLOGICA

Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity

(2016) Alice Melão et al.   HAEMATOLOGICA

The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia

(2016) R. D. Mendes et al.   HAEMATOLOGICA

T-cell acute lymphoblastic leukemia

(2016) E. A. Raetz et al.   Hematology-American Society of Hematology Education Program

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways

(2016) Haluk Yuzugullu et al.   Cell Discovery

IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias

(2016) Samuel Gusscott et al.   PLoS One

Signalling to eIF4E in cancer

(2015) N. Siddiqui et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia

(2015) Diana Passaro et al.   CANCER CELL

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

(2015) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363

(2015) James W. T. Yates et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

(2015) N. Daver et al.   CLINICAL CANCER RESEARCH

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

(2015) C. P. Hall et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy

(2015) A. M. Eiden et al.   CLINICAL CANCER RESEARCH

Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells

(2015) Huibo Li et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia

(2015) Beth A. Lubeck et al.   JOURNAL OF IMMUNOLOGY

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy

(2015) Esperanza Arias et al.   MOLECULAR CELL

Oncogenic PTEN functions and models in T-cell malignancies

(2015) M Tesio et al.   ONCOGENE

RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines

(2015) O Ksionda et al.   ONCOGENE

Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: A new approach for target discovery

(2015) Naomi E. van der Sligte et al.   PROTEOMICS

Regulation of mTORC1 by PI3K signaling

(2015) Christian C. Dibble et al.   TRENDS IN CELL BIOLOGY

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

(2015) C Papayannidis et al.   Blood Cancer Journal

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

(2015) Arindam P. Ghosh et al.   Oncotarget

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia

(2015) Stefano Iacovelli et al.   Oncotarget

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

(2014) S. Schubbert et al.   CANCER RESEARCH

Genome-wide Mapping and Characterization of Notch-Regulated Long Noncoding RNAs in Acute Leukemia

(2014) Thomas Trimarchi et al.   CELL

Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways

(2014) Dalila Naci et al.   CELLULAR SIGNALLING

Rictor/mammalian target of rapamycin 2 regulates the development of notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3

(2014) Chunlan Hua et al.   EXPERIMENTAL HEMATOLOGY

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review)

(2014) CAMILLA EVANGELISTI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

p27 and Leukemia: Cell Cycle and Beyond

(2014) Anita Roy et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia

(2014) A Schwarzer et al.   ONCOGENE

Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells

(2014) T. Hoshii et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review)

(2013) YU-XIN LIAO et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Notch1 Receptor Regulates AKT Protein Activation Loop (Thr308) Dephosphorylation through Modulation of the PP2A Phosphatase in Phosphatase and Tensin Homolog (PTEN)-null T-cell Acute Lymphoblastic Leukemia Cells

(2013) Eric C. Hales et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Notch1Gene Mutations Target KRAS G12D-expressing CD8+Cells and Contribute to Their Leukemogenic Transformation

(2013) Guangyao Kong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

(2013) F Buontempo et al.   LEUKEMIA

Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia

(2013) S Gachet et al.   LEUKEMIA

Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosisin vitroand in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways

(2013) Kang-Ni Wu et al.   LEUKEMIA & LYMPHOMA

Distinct sensitivity of CD8+CD4− and CD8+CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model

(2013) Yingchi Zhang et al.   LEUKEMIA RESEARCH

Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis

(2013) C. Hartzell et al.   Science Signaling

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

(2013) P. Casado et al.   Science Signaling

Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia

(2012) Catherine M. Sawai et al.   CANCER CELL

A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia

(2012) L-N Zhang et al.   CANCER GENE THERAPY

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia

(2012) Keunwook Lee et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

(2012) C Shepherd et al.   LEUKEMIA

Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL

(2012) Samuel Gusscott et al.   LEUKEMIA RESEARCH

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney

(2011) Laura R. Pearce et al.   BIOCHEMICAL JOURNAL

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

(2011) M. Schrappe et al.   BLOOD

Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors

(2011) Ana Batista et al.   EXPERIMENTAL HEMATOLOGY

Pharmacological and Genetic Evaluation of Proposed Roles of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK), Extracellular Signal-regulated Kinase (ERK), and p90RSKin the Control of mTORC1 Protein Signaling by Phorbol Esters

(2011) Bruno D. Fonseca et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway

(2011) Sei Yoshida et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

(2011) Hind Medyouf et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia

(2011) Alejandro Gutierrez et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanisms by Which the Extracellular Matrix and Integrin Signaling Act to Regulate the Switch Between Tumor Suppression and Tumor Promotion

(2011) Patricia J. Keely   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

(2011) C Evangelisti et al.   LEUKEMIA

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

(2011) L Willems et al.   LEUKEMIA

Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin

(2011) Lauren J. Akers et al.   LEUKEMIA RESEARCH

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis

(2011) Chong Zhang et al.   LEUKEMIA RESEARCH

Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells

(2010) Sven A. Lang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis

(2010) Ling Gu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib

(2010) C Biagi et al.   LEUKEMIA

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

(2010) Konstantinos J. Mavrakis et al.   NATURE CELL BIOLOGY

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model

(2009) K. Cullion et al.   BLOOD

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells

(2009) Giovanni Di Maira et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Emerging common themes in regulation of PIKKs and PI3Ks

(2009) Harri Lempiäinen et al.   EMBO JOURNAL

CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia

(2009) Silvia Buonamici et al.   NATURE

The nuts and bolts of AGC protein kinases

(2009) Laura R. Pearce et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration

(2008) Hisaki Hayashi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases

(2008) I. Joshi et al.   BLOOD

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

(2008) D. T. Teachey et al.   BLOOD

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to  -secretase inhibitors

(2008) T. Kindler et al.   BLOOD

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

Regulation of Proline-rich Akt Substrate of 40 kDa (PRAS40) Function by Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation

(2008) Lifu Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1

(2008) Xiaoyu Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

(2008) C. G. Mullighan et al.   SCIENCE